J
Jean-Christophe Sabourin
Researcher at French Institute of Health and Medical Research
Publications - 200
Citations - 9372
Jean-Christophe Sabourin is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: KRAS & Cancer. The author has an hindex of 43, co-authored 183 publications receiving 8474 citations. Previous affiliations of Jean-Christophe Sabourin include Institut Gustave Roussy & Institut de radioprotection et de sûreté nucléaire.
Papers
More filters
Journal ArticleDOI
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik,Bernhard Mlecnik,Bernhard Mlecnik,Gabriela Bindea,Gabriela Bindea,Gabriela Bindea,Helen K. Angell,Pauline Maby,Mihaela Angelova,David Tougeron,Sarah E. Church,Sarah E. Church,Sarah E. Church,Lucie Lafontaine,Lucie Lafontaine,Lucie Lafontaine,Maria Fischer,Tessa Fredriksen,Tessa Fredriksen,Tessa Fredriksen,Maristella Sasso,Maristella Sasso,Maristella Sasso,Amélie M. Bilocq,Amélie M. Bilocq,Amélie M. Bilocq,Amos Kirilovsky,Amos Kirilovsky,Amos Kirilovsky,Anna C. Obenauf,Mohamad Hamieh,Anne Berger,Patrick Bruneval,Jean-Jacques Tuech,Jean-Christophe Sabourin,Florence Le Pessot,Jacques Mauillon,Arash Rafii,Pierre Laurent-Puig,Pierre Laurent-Puig,Michael R. Speicher,Zlatko Trajanoski,Pierre Michel,Richard Sesboüé,Thierry Frebourg,Thierry Frebourg,Franck Pagès,Viia Valge-Archer,Viia Valge-Archer,Jean-Baptiste Latouche,Jérôme Galon,Jérôme Galon,Jérôme Galon +52 more
TL;DR: Assessment of the immune status via Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability staging that could be an important guide for immunotherapy strategies.
Journal ArticleDOI
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi,Julien Mazieres,Jean-Philippe Merlio,Didier Debieuvre,Jean Mosser,Hervé Lena,L'Houcine Ouafik,Benjamin Besse,Isabelle Rouquette,Virginie Westeel,Fabienne Escande,Isabelle Monnet,Antoinette Lemoine,Remi Veillon,Hélène Blons,Clarisse Audigier-Valette,Pierre-Paul Bringuier,R. Lamy,Michèle Beau-Faller,Jean-Louis Pujol,Jean-Christophe Sabourin,Frédérique Penault-Llorca,Marc G. Denis,Sylvie Lantuejoul,Franck Morin,Quân Tran,P. Missy,Alexandra Langlais,Bernard Milleron,Jacques Cadranel,Jean-Charles Soria,Gérard Zalcman +31 more
TL;DR: The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this nationwide molecular profiling of patients with advanced NSCLC provides a clinical benefit.
Journal ArticleDOI
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
F. Di Fiore,F. Blanchard,Françoise Charbonnier,F. Le Pessot,A. Lamy,M.P. Galais,L Bastit,Audrey Killian,Richard Sesboüé,Jean-Jacques Tuech,A.-M. Queuniet,Bernard Paillot,Jean-Christophe Sabourin,Francis Michot,Pierre Michel,Thierry Frebourg +15 more
TL;DR: It is confirmed that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
Journal ArticleDOI
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Frédéric Bibeau,Evelyne Lopez-Crapez,Frédéric Di Fiore,Simon Thezenas,Marc Ychou,Aude Lamy,Frédérique Penault-Llorca,Thierry Frebourg,Pierre Michel,Jean-Christophe Sabourin,Florence Boissière-Michot +10 more
TL;DR: Combined FcGammaRIIa/FcgammaRIIIa polymorphisms are prognostic factors for disease progression in mCRC patients treated with cetuximab plus irinotecan and were independent risk factors for PFS.
Journal ArticleDOI
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Emmanuel Mitry,Eric Baudin,Michel Ducreux,Jean-Christophe Sabourin,P Rufié,T. Aparicio,P. Lasser,Dominique Elias,Pierre Duvillard,Martin Schlumberger,Ph. Rougier +10 more
TL;DR: It is confirmed that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination, however, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed.